UNSPSC 51351507: Hydroxyprogesterone caproate

This classification denotes a therapeutic progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 276F2O42F5. European Medicines Agency schedules Hydroxyprogesterone caproate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08082MIG. Hydroxyprogesterone caproate generally arises in the molecular formula C27H40O4.

UNSPSC 51351507 Hydroxyprogesterone caproate is a Commodity code for a synthetic progestin used primarily in obstetric care to reduce the risk of preterm birth in pregnant women with a history of singleton preterm delivery. State and local governments procure this pharmaceutical through their health departments, Medicaid agencies, public health clinics, and hospital systems to support maternal health programs and ensure access for eligible pregnant patients. The drug is typically acquired through state pharmaceutical contracts, group purchasing organizations, or direct vendor agreements negotiated by state health agencies or hospital purchasing cooperatives. Procurement focuses on securing reliable supply at competitive pricing, often with volume commitments tied to patient census and clinical utilization projections across multiple delivery sites or regional health networks.

The source provided contains no recent state or local contract opportunities under this code. Without posted RFPs, RFQs, IFBs, or ITBs naming hydroxyprogesterone caproate or identifying issuing bodies, geographic activity patterns, or response dates, no representative solicitations or jurisdictional concentration can be characterized from current market data.